Pharmacy Question for the Week of September 18, 2017

Pharmacy Compliance Question of the Week

Question:

What code and modifier should be used to report an injection of the biosimilar drug infliximab?

Answer:

Q5102 (effective April 5, 2016) can be reported with either the existing modifier ZB (Pfizer/Hospira, effective April 1, 2016) or new modifier ZC (Merck/Samsung Bioepis, effective July 1, 2017).

Disclaimer: Every reasonable effort was made to ensure the accuracy of this information at the time it was published. However, due to the nature of industry changes over time we cannot guarantee its validity after the year it was published.